See more : Acerus Pharmaceuticals Corporation (ASPCF) Income Statement Analysis – Financial Results
Complete financial analysis of CEN Biotech, Inc. (CENBF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CEN Biotech, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Permascand Top Holding AB (publ) (PSCAND.ST) Income Statement Analysis – Financial Results
- GIB Capital Group, Inc. (GIBX) Income Statement Analysis – Financial Results
- Saab AB (publ) (SAAB-B.ST) Income Statement Analysis – Financial Results
- Mitshi India Limited (MITSHI.BO) Income Statement Analysis – Financial Results
- Hao Wen Holdings Limited (8019.HK) Income Statement Analysis – Financial Results
CEN Biotech, Inc. (CENBF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.cenbiotechinc.com
About CEN Biotech, Inc.
CEN Biotech, Inc. focuses on the manufacture, production, and development of light emitting diode lighting technology and hemp-based products. It intends to cultivate hemp for usage in industrial, medical, and food products; and to provide digital marketing and web design related services. The company was incorporated in 2013 and is based in Windsor, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 987.11K | 626.87K | 0.00 | 0.00 | 0.00 | 0.00 | 2.32K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 489.11K | 0.00 | 2.54M | 2.58M | 4.37M | 11.61M | 142.93K | 0.00 | 0.00 | 0.00 |
| Gross Profit | 498.00K | 626.87K | -2.54M | -2.58M | -4.37M | -11.61M | -140.61K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 50.45% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | -6,058.08% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 41.00K | 32.00K | 0.00 | 0.00 | 643.50K | 0.00 |
| General & Administrative | 2.25M | 18.33M | 2.21M | 2.58M | 3.10M | 11.61M | 1.10M | 1.17M | 3.01M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 2.25M | 18.33M | 2.21M | 2.58M | 3.10M | 11.61M | 1.10M | 1.17M | 3.01M | 570.72K |
| Other Expenses | 0.00 | -360.31K | 20.52M | 290.00K | -390.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 2.25M | 18.33M | 2.21M | 2.58M | 3.10M | 11.61M | 1.10M | 1.17M | 3.01M | 570.72K |
| Cost & Expenses | 2.25M | 18.33M | 2.21M | 2.58M | 3.10M | 11.61M | 1.10M | 1.17M | 3.01M | 570.72K |
| Interest Income | 612.00 | 504.00 | 6.40K | 8.25K | 9.40K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 252.77K | 846.75K | 3.68M | 3.31M | 2.87M | 2.38M | 1.60M | 1.36M | 134.84K | 0.00 |
| Depreciation & Amortization | 489.11K | 461.71K | 435.54K | 443.20K | 439.04K | 426.58K | 142.93K | -121.15K | 3.01M | 570.72K |
| EBITDA | -772.96K | -17.63M | 18.36M | -1.84M | -4.22M | -11.61M | -6.49M | -1.17M | -150.17K | 0.00 |
| EBITDA Ratio | -78.30% | -2,808.22% | 0.00% | 0.00% | 0.00% | 0.00% | -45,330.29% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.26M | -19.04M | 18.32M | -2.58M | -4.37M | -11.61M | -5.98M | -1.04M | -3.01M | -570.72K |
| Operating Income Ratio | -128.14% | -3,036.93% | 0.00% | 0.00% | 0.00% | 0.00% | -257,684.45% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -249.99K | 97.53K | 16.46M | -3.08M | -4.43M | -2.47M | -6.39M | -1.36M | -150.17K | 0.00 |
| Income Before Tax | -1.51M | -18.94M | 14.25M | -5.66M | -7.53M | -14.08M | -7.58M | -2.41M | -3.16M | -570.72K |
| Income Before Tax Ratio | -153.46% | -3,021.38% | 0.00% | 0.00% | 0.00% | 0.00% | -326,670.75% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -36.36K | 24.20M | 3.60M | -288.64K | 2.38M | 1.60M | 1.48M | -2.88M | 0.00 |
| Net Income | -1.51M | -18.90M | -9.95M | -9.25M | -7.53M | -14.08M | -7.58M | -2.41M | -3.16M | -570.72K |
| Net Income Ratio | -153.46% | -3,015.58% | 0.00% | 0.00% | 0.00% | 0.00% | -326,670.75% | 0.00% | 0.00% | 0.00% |
| EPS | -0.02 | -0.45 | -0.36 | -0.35 | -0.30 | -1.68 | -0.92 | -0.34 | -12.68 | -0.08 |
| EPS Diluted | -0.02 | -0.45 | -0.30 | -0.35 | -0.30 | -1.68 | -0.92 | -0.34 | -12.68 | -0.08 |
| Weighted Avg Shares Out | 64.74M | 42.42M | 27.26M | 26.36M | 25.30M | 8.40M | 8.22M | 7.00M | 249.39K | 7.00M |
| Weighted Avg Shares Out (Dil) | 64.74M | 42.42M | 32.73M | 26.36M | 25.30M | 8.40M | 8.22M | 7.00M | 249.39K | 7.00M |
CEN Biotech Inc. Announces Planned Strategic Expansion of Business and Closing of Clear Com Media Inc. Acquisition
Source: https://incomestatements.info
Category: Stock Reports